On October 23, HANSOH PHARMA recorded an Intraday Rise of 3.01% in Regular Trading, with the shares trading at HK$32.84 and turnover at HK$306 million.
The clearest catalyst in publicly available information is a same-day broker note reiterating an outperform rating and a HK$52.00 target price, arguing that the company’s large Roche deal further validates the global competitiveness of its ADC platform and could boost profit and cash flow through the upfront payment while supporting longer-term milestone and royalty income.
Background details show HANSOH PHARMA recently signed a second ADC strategic collaboration and licensing agreement with Roche covering two preclinical ADC programs and multiple Roche-nominated targets. The deal includes a US$400 million upfront payment, an additional US$110 million one-year payment, and potential development, regulatory and commercialization milestones exceeding US$15 billion, with tiered royalties. Several other brokers also lifted or maintained target prices around HK$50 to HK$52.70, reinforcing the platform-level nature of the partnership.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments